PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort

Cardiovascular Diabetology

Diethelm Tschoepe²  Wolfgang Rathmann¹  Rui Wang-Sattler⁶  Heinz-Erich Wichmann⁸  Thomas Illig³  Wolfgang Koenig⁴  Annette Peters⁷  Harald Grallert⁶  Christian Herder⁵  Michael Roden⁵  Barbara Menart⁵  Christa Meisinger⁷  Tao Xu⁶  Bernd Stratmann² 

[1] Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany;Heart and Diabetes Center NRW, Ruhr University Bochum, Georgstr. 11, D-32545 Bad Oeynhausen, Germany;Hannover Unified Biobank, Hannover Medical School, Hannover, Germany;Department Internal Medicine II, University Clinic Ulm, Ulm, Germany;Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University, Duesseldorf, Germany;Research Unit of Molecular Epidemiology, Helmholtz Zentrum Muenchen, German Research Center of Environmental Health, Neuherberg, Germany;Institute of Epidemiology II, Helmholtz Zentrum Muenchen, German Research Center of Environmental Health, Neuherberg, Germany;Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany

关键词: Epidemiology;    Glycemic management;    All-cause mortality;    Mean platelet volume;    Platelet glycoprotein receptor polymorphism;    Glycated hemoglobin;   

Others  :  792992
DOI  :  10.1186/1475-2840-13-90

 received in 2014-02-13, accepted in 2014-04-28,  发布年份 2014

【 摘 要 】

Objective

The genetic polymorphism concerning the ß3-subunit of platelet integrin receptor glycoprotein IIIa is held responsible for enhanced binding of adhesive proteins resulting in increased thrombogenic potential. Whether it is associated with mortality, HbA1c or platelet volume is tested prospectively in an epidemiological cohort.

Research design and methods

Population-based Cooperative Health Research in the Region of Augsburg (KORA) S4-Survey (N = 4,028) was investigated for prognostic value of PLA1A2-polymorphism regarding all-cause mortality, correlation with HbA_1c, and mean platelet volume. Multivariate analysis was performed to investigate association between genotype and key variables.

Results

Prevalence of thrombogenic allele variant PLA2 was 15.0%. Multivariate analysis revealed no association between PLA1A2 polymorphism and mortality in the KORA-cohort. HbA_1c was a prognostic marker of mortality in non-diabetic persons resulting in J-shaped risk curve with dip at HbA_1c = 5.5% (37 mmol/mol), confirming previous findings regarding aged KORA-S4 participants (55–75 years). PLA1A2 was significantly associated with elevated HbA_1c levels in diabetic patients (N = 209) and reduced mean platelet volume in general population. In non-diabetic participants (N = 3,819), carriers of PLA2 allele variant presenting with HbA_1c > 5.5% (37 mmol/mol) showed higher relative risk of mortality with increasing HbA_1c.

Conclusion

PLA1A2 polymorphism is associated with mortality in participants with HbA_1c ranging from 5.5% (37 mmol/mol) to 6.5% (48 mmol/mol). Maintenance of euglycemic control and antiplatelet therapy are therefore regarded as effective primary prevention in this group.

【 授权许可】

   
2014 Stratmann et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Stratmann B, Tschoepe D: Atherogenesis and atherothrombosis–focus on diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009, 23:291-303.
• [2]Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ: Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997, 96:1424-1431.
• [3]Park Y, Schoene N, Harris W: Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002, 13:301-306.
• [4]Vizioli L, Muscari S, Muscari A: The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract 2009, 63:1509-1515.
• [5]Shah B, Sha D, Xie D, Mohler ER 3rd, Berger JS: The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the national health and nutrition examination survey, 1999–2004. Diabetes Care 2012, 35:1074-1078.
• [6]Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD: Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011, 17:47-58.
• [7]Bath PM: The routine measurement of platelet size using sodium citrate alone as the anticoagulant. Thromb Haemost 1993, 70:687-690.
• [8]Dastjerdi MS, Emami T, Najafian A, Amini M: Mean platelet volume measurement, EDTA or citrate? Hematology 2006, 11:317-319.
• [9]O’Brien JR: Letter: A relationship between platelet volume and platelet number. Thromb Diath Haemorrh 1974, 31:363-365.
• [10]Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T: Correlation between mean platelet volume and fasting plasma glucose levels in prediabetic and normoglycemic individuals. Cardiovasc Diabetol 2013, 12:14. BioMed Central Full Text
• [11]Kim JH, Kang SB, Kang JI, Kim JW, Kim SY, Bae HY: The relationship between mean platelet volume and fasting plasma glucose differs with glucose tolerance status in a Korean general population: gender differences. Platelets 2013, 24:469-473.
• [12]Vernekar PV, Vaidya KA: Comparison of mean platelet volume in type 2 diabetics on insulin therapy and on oral hypoglycemic agents. J Clin Diagn Res 2013, 7:2839-2840.
• [13]Newman PJ, Derbes RS, Aster RH: The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989, 83:1778-1781.
• [14]Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996, 334:1090-1094.
• [15]Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995, 332:1553-1559.
• [16]Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D’Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH: Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: the framingham offspring study. Arterioscler Thromb Vasc Biol 1999, 19:1142-1147.
• [17]Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF: Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000, 101:1013-1018.
• [18]Zhu MM, Weedon J, Clark LT: Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000, 86:1000-1005. A1008
• [19]Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ: A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003, 22:1741-1760.
• [20]Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, Mehilli J, Schomig K, Von Beckerath N: PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999, 99:1005-1010.
• [21]le Hello C, Morello R, Lequerrec A, Duarte C, Riddell J, Hamon M: Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J 2007, 5:19. BioMed Central Full Text
• [22]Undas A, Sanak M, Musial J, Szczeklik A: Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999, 353:982-983.
• [23]Tschoepe D, Menart B, Ferber P, Altmann C, Haude M, Haastert B, Roesen P: Genetic variation of the platelet- surface integrin GPIIb-IIIa (PIA1/A2-SNP) shows a high association with Type 2 diabetes mellitus. Diabetologia 2003, 46:984-989.
• [24]Marz W, Boehm BO, Winkelmann BR, Hoffmann MM: The PlA1/A2 polymorphism of platelet glycoprotein IIIa is not associated with the risk of type 2 diabetes. The Ludwigshafen Risk and Cardiovascular Health study. Diabetologia 2004, 47:1969-1973.
• [25]Schwippert-Houtermans B, Strapatsakis S, Roesen P, Tschoepe D: Evaluation of an antibody-based genotype classification of the platelet fibrinogen receptor (GPIIb/IIIa). Cytometry 2001, 46:238-242.
• [26]Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G: High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003, 46:182-189.
• [27]Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, Davidson MB, DeFronzo R, Genuth S, Holman RR, Ji L, Kirkman S, Knowler WC, Schatz D, Shaw J, Sobngwi E, Steffes M, Vaccaro O, Wareham N, Zinman B, Kahn R: International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
• [28]Kowall B, Rathmann W, Heier M, Giani G, Peters A, Thorand B, Huth C, Icks A, Meisinger C: Categories of glucose tolerance and continuous glycemic measures and mortality. Eur J Epidemiol 2011, 26:637-645.
• [29]Reiner AP, Siscovick DS, Rosendaal FR: Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001, 5:262-287. discussion 311–262
• [30]Monteiro PF, Morganti RP, Delbin MA, Calixto MC, Lopes-Pires ME, Marcondes S, Zanesco A, Antunes E: Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovasc Diabetol 2012, 11:5. BioMed Central Full Text
• [31]Galasso G, Santulli G, Piscione F, de Rosa R, Trimarco V, Piccolo R, Cassese S, Iaccarino G, Trimarco B, Chiariello M: The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events. BMC Cardiovasc Disord 2010, 10:41. BioMed Central Full Text
• [32]Kunicki TJ, Nugent DJ: The genetics of normal platelet reactivity. Blood 2010, 116:2627-2634.
• [33]Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, Rosskopf D, Lichtner P, Klopp N, Stephens J, Watkins NA, Deloukas P, Greinacher A, Koenig W, Nauck M, Rimmbach C, Völzke H, Peters A, Illig T, Ouwehand WH, Meitinger T, Wichmann HE, Döring A: A genome-wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet 2009, 84:66-71.
• [34]Weiss LA, Veenstra-Vanderweele J, Newman DL, Kim SJ, Dytch H, McPeek MS, Cheng S, Ober C, Cook EH Jr, Abney M: Genome-wide association study identifies ITGB3 as a QTL for whole blood serotonin. Eur J Hum Genet 2004, 12:949-954.
• [35]Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001, 322:15-18.
• [36]Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, Olofsson B, Pfeffer MA, Yusuf S: The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med 2008, 168:1699-1704.
• [37]Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbjornsdottir S, Eliasson B: New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med 2010, 268:471-482.
• [38]Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW: Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005, 165:1910-1916.
• [39]Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362:800-811.
• [40]Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD: Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
• [41]Carson AP, Fox CS, McGuire DK, Levitan EB, Laclaustra M, Mann DM, Muntner P: Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes. Circ Cardiovasc Qual Outcomes 2010, 3:661-667.
• [42]Greenfield S, Billimek J, Pellegrini F, Franciosi M, de Berardis G, Nicolucci A, Kaplan SH: Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med 2009, 151:854-860.
• [43]Doerr R, Hoffmann U, Otter W, Heinemann L, Hunger-Battefeld W, Kulzer B, Klinge A, Lodwig V, Amann-Zalan I, Sturm D, Tschoepe D, Spitzer SG, Stumpf J, Lohmann T, Schnell O: Oral glucose tolerance test and HbA(1)c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study. Diabetologia 2011, 54:2923-2930.
• [44]Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr, GREAT Network: Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol 2013, 61:820-829.